CENGILD MEDICAL BERHAD announced a quarterly dividend of RM 0.0060 per share. The dividend is payable on 28-Feb-2025, while the ex-date will be on 12-Feb-2025. This is higher than the previous dividend of RM 0.0037 per share, with ex-date of 10-Sep-2024 and paid to the shareholders on 27-Sep-2024.
Ann. Date
Ex Date
Amount
Payment Date
About CENGILD MEDICAL BERHAD
Cengild Medical Berhad is a Malaysia-based investment holding company. The Company through its subsidiary, is a healthcare provider specializing in the diagnosis and treatment of gastrointestinal and liver disease. Its medical center's business activities comprise of consultant services and medical management services, which includes nursing services and clinical support services. Its medical center facilities offers 10 clinics, three endoscopy rooms, 28 beds (which include eight-day care beds), special diagnostic (treadmill stress test and echocardiography) department, two operating theatres, radiology department, accident and emergency department, pharmacy, laboratory, and central sterile supply department. In addition, it also offers 24-hour outpatient accident and emergency service, health screening, physiotherapy and histopathology services. Its imaging facilities includes fibro scan, ultrasonography, CT scan, fluoroscopy, and angiography equipment.
How to be entitled
To be entitled for any of the above, you need to purchase the shares one trading day before the ex-Date. You will not be entitled for the above if you purchase the shares on or after the ex-Date.
On ex-Date, the price will be adjusted to reflect the theoretical market price of the stock after the entitlement. You can sell the shares on / after ex-Date and still be entitled to the corporate exercise. The key is to purchase the shares before ex-Date.
How to apply
No application is needed. Shareholders that fulfill the requirement above will receive the dividend in their registered bank account on the payment date automatically.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....